The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) hit a new 52-week low and has $4.44 target or 10.00% below today’s $4.93 share price. The 8 months bearish chart indicates high risk for the $104.83 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $4.44 price target is reached, the company will be worth $10.48M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 78,645 shares traded hands or 375.66% up from the average. Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has declined 38.38% since April 1, 2016 and is downtrending. It has underperformed by 39.60% the S&P500.
Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) Ratings Coverage
Out of 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $22 is the highest target while $10 is the lowest. The $16.25 average target is 229.61% above today’s ($4.93) stock price. Nabriva Therapeutics has been the topic of 7 analyst reports since October 12, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, October 12 by Needham. RBC Capital Markets maintained Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) rating on Thursday, November 12. RBC Capital Markets has “Outperform” rating and $22 price target. The stock has “Outperform” rating given by Leerink Swann on Thursday, October 27. The rating was initiated by RBC Capital Markets on Tuesday, October 13 with “Outperform”. The firm has “Buy” rating by Gabelli given on Wednesday, January 27. The firm earned “Outperform” rating on Tuesday, October 13 by Wedbush. On Tuesday, October 13 the stock rating was initiated by Leerink Swann with “Outperform”.
According to Zacks Investment Research, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.”
More recent Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) news were published by: Benzinga.com which released: “Leerink: Time To Buy Nabriva Therapeutics’ ‘Unique Differentiation'” on October 13, 2015. Also Benzinga.com published the news titled: “Benzinga’s Top Initiations” on October 27, 2016. Investorplace.com‘s news article titled: “11 Pharmaceuticals Stocks to Sell Now” with publication date: October 21, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.